A First in Human, Three-part, Double Blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate Safety and Pharmacokinetics of TT5 in Healthy Participants and Surgical Patients
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs TT 5 (Primary)
- Indications Pain
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Tafalgie Therapeutics
- 30 Jan 2025 New trial record